We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-9.72%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.67B
AUM Growth
-$658M
Cap. Flow
+$79.2M
Cap. Flow %
1.19%
Top 10 Hldgs %
57.1%
Holding
295
New
64
Increased
76
Reduced
63
Closed
70

Top Buys

Rank Stock Value
1
FRPT icon
Freshpet
FRPT
+$87.7M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.2M
3
STAA icon
STAAR Surgical
STAA
+$42.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$35.7M
5
SNN icon
Smith & Nephew
SNN
+$34.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.1M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$79.9M
3
GSK icon
GSK
GSK
+$73.2M
4
HUM icon
Humana
HUM
+$69.2M
5
BUD icon
AB InBev
BUD
+$68M

Sector Composition

Rank Sector Weight
1 Healthcare 35.45%
2 Consumer Discretionary 6.85%
3 Consumer Staples 5.47%
4 Technology 5.39%
5 Communication Services 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.37B 20.54%
2,450,000
-50,000
-2% -$29.4M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$1.34B 20.03%
6,700,000
-100,000
-1% -$21.7M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$277M 4.15%
5,434,843
-943,157
-15% -$47.1M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.68B
$170M 2.55%
5,196,000
+360,000
+7% +$12.8M
TVTX icon
5
Travere Therapeutics
TVTX
$5.33B
$159M 2.38%
8,872,000
+1,514,000
+21% +$30.7M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.7B
$111M 1.66%
1,000,190
+108,190
+12% +$13.7M
CYTK icon
7
CALL
Cytokinetics
CYTK
$11B
$109M 1.63%
2,700,000
+2,090,000
+343% +$96M
INCY icon
8
Incyte
INCY
$23.5B
$101M 1.52%
1,671,463
-96,367
-5% -$6.72M
MDGL icon
9
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$99.4M 1.49%
+300,000
New +$98.6M
IMVT icon
10
Immunovant
IMVT
$8.09B
$76.9M 1.15%
4,500,000
+629,414
+16% +$13.2M
EXAS
11
DELISTED
Exact Sciences
EXAS
$76.7M 1.15%
1,772,369
+155,369
+10% +$7.87M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$68.8B
$72.3M 1.08%
114,073
+86,028
+307% +$59.2M
GRFS
13
Grifois
GRFS
$5.16B
$66M 0.99%
9,278,000
-758,000
-8% -$5.72M
AGIO icon
14
Agios Pharmaceuticals
AGIO
$2.16B
$60M 0.9%
2,048,000
-216,304
-10% -$7.18M
FRPT icon
15
Freshpet
FRPT
$2.83B
$59.6M 0.89%
+716,960
New +$87.7M
ARGX icon
16
argenx
ARGX
$57.4B
$58M 0.87%
98,000
-26,000
-21% -$16.4M
FIVN icon
17
FIVE9
FIVN
$1.77B
$57M 0.85%
2,098,000
+127,793
+6% +$4.69M
STAA icon
18
STAAR Surgical
STAA
$1.16B
$52.9M 0.79%
3,000,000
+2,128,000
+244% +$42.7M
TMCI icon
19
Treace Medical Concepts
TMCI
$259M
$52.1M 0.78%
6,211,000
+2,000
+0% +$18K
PENN icon
20
PENN Entertainment
PENN
$2.74B
$50.3M 0.75%
3,086,057
-212,211
-6% -$4.15M
SAM icon
21
Boston Beer
SAM
$1.88B
$50.3M 0.75%
210,553
+88,624
+73% +$21.6M
AMZN icon
22
Amazon
AMZN
$2.5T
$50.3M 0.75%
264,126
+79,024
+43% +$17.1M
SNN icon
23
Smith & Nephew
SNN
$12.9B
$50.2M 0.75%
1,769,000
+1,275,000
+258% +$34.1M
MSFT icon
24
Microsoft
MSFT
$2.84T
$49.6M 0.74%
132,000
+36,034
+38% +$14.7M
SPB icon
25
Spectrum Brands
SPB
$2.04B
$49.4M 0.74%
691,000
+115,143
+20% +$9.03M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Armistice Capital held 295 positions worth $6.67B, down 9% from $7.33B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Armistice Capital's Q1 2025 filing shows 64 new, 76 increased, 63 reduced and 70 closed positions. Its largest new stake was Freshpet: 716,960 shares worth $59.6M. The largest sale was Vertex Pharmaceuticals, an estimated $81.1M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 39% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

  • Armistice Capital's largest Q1 2025 buy was Freshpet: 716,960 shares worth $59.6M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q1 2025, an estimated $59.2M increase.
  • Armistice Capital's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $81.1M.
  • Armistice Capital fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $79.9M.
  • Armistice Capital's ten largest holdings make up 57% of its $6.67B portfolio in Q1 2025.
  • Armistice Capital opened 64 new positions and closed 70 in Q1 2025.
  • Armistice Capital's portfolio value fell 9% quarter-over-quarter to $6.67B.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.